rs727504300
Variant summary
Our verdict is Pathogenic. The variant received 11 ACMG points: 11P and 0B. PVS1PM2PP2
The NM_000432.4(MYL2):c.45_46delCAinsT(p.Asn16ThrfsTer34) variant causes a frameshift, missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Uncertain significance (★★). Synonymous variant affecting the same amino acid position (i.e. S15S) has been classified as Likely benign.
Frequency
Consequence
NM_000432.4 frameshift, missense
Scores
Clinical Significance
Conservation
Publications
- hypertrophic cardiomyopathyInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- hypertrophic cardiomyopathy 10Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: ClinGen, G2P, PanelApp Australia, Labcorp Genetics (formerly Invitae)
- myopathy, myofibrillar, 12, infantile-onset, with cardiomyopathyInheritance: AR Classification: MODERATE Submitted by: Ambry Genetics
- congenital fiber-type disproportion myopathyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- dilated cardiomyopathyInheritance: AD Classification: LIMITED Submitted by: ClinGen
- arrhythmogenic right ventricular cardiomyopathyInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 11 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| MYL2 | NM_000432.4 | c.45_46delCAinsT | p.Asn16ThrfsTer34 | frameshift_variant, missense_variant | Exon 2 of 7 | ENST00000228841.15 | NP_000423.2 | |
| MYL2 | NM_001406745.1 | c.45_46delCAinsT | p.Asn16ThrfsTer27 | frameshift_variant, missense_variant | Exon 2 of 6 | NP_001393674.1 | ||
| MYL2 | NM_001406916.1 | c.-13_-12delCAinsT | 5_prime_UTR_variant | Exon 2 of 7 | NP_001393845.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| MYL2 | ENST00000228841.15 | c.45_46delCAinsT | p.Asn16ThrfsTer34 | frameshift_variant, missense_variant | Exon 2 of 7 | 1 | NM_000432.4 | ENSP00000228841.8 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not specified Uncertain:1
Variant classified as Uncertain Significance - Favor Pathogenic. The p.Asn16fs v ariant in MYL2 has been identified by our laboratory in 1 individual with HCM. I t has also been identified in 1/66542 European chromosomes by the Exome Aggregat ion Consortium (ExAC, http://exac.broadinstitute.org). This variant is predicted to cause a frameshift, which alters the protein?s amino acid sequence beginning at position 16 and leads to a premature termination codon 34 amino acids downst ream. This alteration is then predicted to lead to a truncated or absent protein . However, loss of function is not an established disease mechanism for this gen e at this time. In summary, while there is some suspicion for a pathogenic role, the clinical significance of the p.Asn16fs variant is uncertain. -
Hypertrophic cardiomyopathy 10 Uncertain:1
This sequence change creates a premature translational stop signal (p.Asn16Thrfs*34) in the MYL2 gene. It is expected to result in an absent or disrupted protein product. However, the current clinical and genetic evidence is not sufficient to establish whether loss-of-function variants in MYL2 cause disease. This variant is present in population databases (rs781431079, gnomAD 0.002%). This premature translational stop signal has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 27532257). ClinVar contains an entry for this variant (Variation ID: 1359362). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Cardiovascular phenotype Uncertain:1
The c.45_46delCAinsT variant, located in coding exon 2 of the MYL2 gene, results from the deletion of two nucleotides and insertion of one nucleotide causing a translational frameshift with a predicted alternate stop codon (p.N16Tfs*34). This variant was reported in individual(s) with features consistent with hypertrophic cardiomyopathy (HCM) (Walsh R et al. Genet Med, 2017 Feb;19:192-203). Although biallelic loss of function of MYL2 has been associated with autosomal recessive MYL2-related myofibrillar myopathy with cardiomyopathy, haploinsufficiency of MYL2 has not been established as a mechanism of disease for autosomal dominant MYL2-related cardiomyopathy. Based on the supporting evidence, this variant is expected to be causative of autosomal recessive MYL2-related myofibrillar myopathy with cardiomyopathy when present along with a second pathogenic variant on the other allele; however, its clinical significance for autosomal dominant MYL2-related cardiomyopathy is unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at